DREAMM-2 Put GSK’s BCMA Drug In Pole Position In Multiple Myeloma

The DREAMM-2 trial of the antibody-drug conjugate belantamab mafodotin in relapsed/refractory multiple myeloma patients has hit its primary endpoint, giving GSK a chance to file for approval before its BCMA rivals.

Start_Line
GSK DREAMM-ing of a quick start

GlaxoSmithKline PLC’s anti-B-cell maturation antigen (BCMA) therapy has improved outcomes in a pivotal multiple myeloma trial, setting the company up to file for approval by the end of the year.

The asset, belantamab mafodotin, is an anti-BCMA antibody-drug conjugate (ADC) that uses a linker technology licensed from Seattle Genetics Inc.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D